Proposed price cap regulations will impact Canadian R&D, says big pharma, but academic not convinced

Health Canada says the proposed changes to the Patented Medicines Prices Review Board could be between $8-billion and $24-billion over the next decade, but Innovative Medicines Canada's study by PCDI Market Access predicts impacts of $26-billion to $35-billion.

Health Minister Ginette Petitpas Taylor speaks to media before Question Period in October. One of the minister's mandate letter commitments is reducing Canadians' high drug costs. The Hill Times photograph by Andrew Meade

News

BY EMILY HAWS

February 5, 2018

Brand name drug companies are warning the government to think through its proposed regulations for the Patented Medicines Prices Review Board, saying it could curb investment in Canadian research and development. However, one Univ...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Today’s Headlines Newsletter

Your quick scan of the news you need each weekday to be the smartest person in the room.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy